Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products

This study has been completed.
Sponsor:
Information provided by:
Terumo BCTbio
ClinicalTrials.gov Identifier:
NCT00263809
First received: December 7, 2005
Last updated: October 6, 2009
Last verified: October 2009

December 7, 2005
October 6, 2009
December 2005
October 2007   (final data collection date for primary outcome measure)
The platelet corrected count increment measured 1 hour post transfusion.
Same as current
Complete list of historical versions of study NCT00263809 on ClinicalTrials.gov Archive Site
  • The platelet corrected count increment measured 24 hours post-transfusion.
  • The number of days between platelet transfusions during the period of the study.
  • The number of platelet transfusions per subject.
  • The number of platelets infused per subject.
  • The number of platelets used.
  • The frequency of refractoriness to platelet transfusion.
  • In case of refractoriness, the evidence for neoantigen immunization against test product.
  • The number of red blood cell transfusions during the study period.
  • The incidence of serious adverse events in relation to platelet transfusions.
  • The incidence of any adverse events in relation to platelet transfusions.
  • The occurrence of bleeding episodes.
Same as current
Not Provided
Not Provided
 
Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products
Evaluation of the Safety and Performance of Platelet Transfusion Products Treated With MIRASOL® Pathogen Reduction Technology. A Study in Human Thrombocytopenic Subjects.

The primary objective of the study is to measure platelet corrected count increments and the incidence of serious adverse events (SAE). The primary endpoint is the platelet corrected count increment measured 1-hour post transfusion in response to the infusion of platelet concentrates treated with the Mirasol PRT System device (test product) versus untreated (reference product).

The objective of the study is to determine if the MIRASOL Pathogen Reduction Technology (PRT) System for Platelets device performs safely and maintains adequate platelet performance in a clinical setting. This will be achieved by comparing the platelet corrected count increment measured 1 hour post transfusion and the incidence of serious adverse events in response to the infusion of platelet concentrates treated with the device (test product) versus untreated (reference product) in thrombocytopenic subjects requiring platelet transfusions. The performance, safety, and tolerability profile of the device will be further assessed by monitoring and comparing the incidence of discontinuations due to adverse events in relation to platelet transfusion up to 4 weeks after transfusion, including the incidence of transfusion associated infections, and the number and time between transfusions.

Interventional
Phase 0
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Thrombocytopenia
Device: Pathogen Reduction Technology
  • Experimental: 1
    Treatment, Mirasol-treated platelets
    Intervention: Device: Pathogen Reduction Technology
  • No Intervention: 2
    Reference, Untreated platelets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
118
October 2007
October 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female of age of 16 years or older
  • Women of Child Bearing Potential not pregnant
  • Subject must have signed and dated the Informed Consent form
  • Hospitalized, thrombocytopenic subjects and expected to receive at least two platelets transfusion

Exclusion Criteria:

  • History of any hypersensitivity reaction to riboflavin or metabolites
  • History of refractoriness to platelet transfusions
  • Positive lymphocytotoxic antibody test
  • Active bleeding
  • Splenomegaly
  • Acute or chronic Disseminated Intravascular Coagulation
  • History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenia Purpura, or Haemolytic Uremic Syndrome
  • History or diagnosis of an autoimmune disease affecting haemostasis
  • History of solid organ transplants
  • Evidence of occlusive venous disease
  • Clinical signs of infection at the time of inclusion
  • Pregnant or lactating females
  • Chronic alcohol misuse
  • Use of prohibited medications
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT00263809
CTS-0028
Not Provided
Tracy Roberts, Director of Clinical Affairs, Navigant Biotechnologies
Terumo BCTbio
Not Provided
Principal Investigator: Jean-Pierre Cazenave, MD Director - EFS Alsace - France
Terumo BCTbio
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP